Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide.
Starpharma Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.17|
|52 Week High||AU$1.13|
|52 Week Low||AU$2.52|
|1 Month Change||-18.53%|
|3 Month Change||-8.98%|
|1 Year Change||-22.07%|
|3 Year Change||-18.82%|
|5 Year Change||77.86%|
|Change since IPO||45.63%|
Recent News & Updates
We Think Starpharma Holdings (ASX:SPL) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
|SPL||AU Pharmaceuticals||AU Market|
Return vs Industry: SPL underperformed the Australian Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: SPL underperformed the Australian Market which returned 20.3% over the past year.
Stable Share Price: SPL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: SPL's weekly volatility (7%) has been stable over the past year.
About the Company
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray.
Starpharma Holdings Fundamentals Summary
|SPL fundamental statistics|
Is SPL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SPL income statement (TTM)|
|Cost of Revenue||AU$15.87m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.049|
|Net Profit Margin||-917.34%|
How did SPL perform over the long term?See historical performance and comparison
Is Starpharma Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SPL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SPL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SPL is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: SPL is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SPL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SPL is overvalued based on its PB Ratio (7.6x) compared to the AU Pharmaceuticals industry average (3.5x).
How is Starpharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Starpharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Starpharma Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SPL is currently unprofitable.
Growing Profit Margin: SPL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SPL is unprofitable, but has reduced losses over the past 5 years at a rate of 0.2% per year.
Accelerating Growth: Unable to compare SPL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: SPL has a negative Return on Equity (-31.67%), as it is currently unprofitable.
How is Starpharma Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: SPL's short term assets (A$70.8M) exceed its short term liabilities (A$10.4M).
Long Term Liabilities: SPL's short term assets (A$70.8M) exceed its long term liabilities (A$509.0K).
Debt to Equity History and Analysis
Debt Level: SPL is debt free.
Reducing Debt: SPL has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SPL has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 9.8% each year
What is Starpharma Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SPL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SPL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SPL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jackie Fairley (58 yo)
Dr. Jacinth K. Fairley, also known as Jackie, B.Sc., B.V.Sc.(Hons), MBA, GAICD, FTSE, has been the Chief Executive Officer of Starpharma Holdings Limited since July 1, 2006 and serves as its Managing Direc...
CEO Compensation Analysis
Compensation vs Market: Jackie's total compensation ($USD1.15M) is above average for companies of similar size in the Australian market ($USD732.79K).
Compensation vs Earnings: Jackie's compensation has increased whilst the company is unprofitable.
Experienced Board: SPL's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SPL insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Starpharma Holdings Limited's employee growth, exchange listings and data sources
- Name: Starpharma Holdings Limited
- Ticker: SPL
- Exchange: ASX
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$473.267m
- Shares outstanding: 406.24m
- Website: https://starpharma.com
Number of Employees
- Starpharma Holdings Limited
- 4-6 Southampton Crescent
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 07:04|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.